January 5, 2024 News by Lindsey Shapiro, PhD FDA OKs Phase 2 clinical trial of KYV-101 for progressive MS The U.S. Food and Drug Administration (FDA) has cleared a Phase 2 clinical trial to test Kyverna Therapeutics‘ cell-based therapy candidate KYV-101 in people with treatment-resistant progressive multiple sclerosis (MS). Called KYSA-7 (NCT06138132), the open-label trial will enroll an estimated 12 patients with either primary progressive…
December 1, 2023 News by Andrea Lobo, PhD FDA clears BrainSpec’s tool to measure metabolites on brain scans The U.S. Food and Drug Administration (FDA) has cleared BrainSpec Core, a platform that performs non-invasive measurements of brain chemistry, for use in diagnosing some of the most common diseases that affect the brain, including multiple sclerosis (MS). Developed by BrainSpec, the platform uses magnetic resonance spectroscopy (MRS)…
November 27, 2023 News by Marisa Wexler, MS FDA clears AI tool for detecting disease activity on MRI scans Pixyl.Neuro, a next-generation software that uses artificial intelligence (AI) in analyzing MRI scans to help detect and monitor multiple sclerosis (MS) disease activity, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for clinical use. 510(k) clearance is required for medical devices used in the…
March 11, 2022 News by Marta Figueiredo, PhD FDA Clears Leg-worn ‘Neural Sleeve’ to Aid Walking Cionic has received authorization from the U.S. Food and Drug Administration (FDA) to market its lightweight, leg-worn Neural Sleeve to improve walking in people with multiple sclerosisĀ (MS) and other conditions that affect mobility. The decision comes four months after the company submitted the device ā the first to…
January 14, 2022 News by Yedida Y Bogachkov PhD Trial of Cannabidiol-derived EHP-101 for Relapsing MS Enrolling Soon Emerald Health Pharmaceuticals will soon begin enrollment in a Phase 2a clinical trial investigating its cannabidiol-derived therapy EHP-101 in relapsing forms of multiple sclerosis (MS). The trial (NCT04909502) aims to recruit 50 patients, ages 18-55, with relapsing-remitting MS (RRMS) and active secondary progressive MS (SPMS).
February 15, 2017 News by Patricia Silva, PhD FDA OKs Bioness’ Electrical-stimulation Rehabilitation Device for Gait Impairment The U.S. Food and Drug Administration (FDA) has authorized the use ofĀ Bionessā L300 Go System electrical-stimulation rehabilitation device for multiple sclerosis (MS)Ā patients and others with walking impairment. It is the first electrical stimulation deviceĀ to offer 3D motion detection of gait and muscle activation, the company says. The L300…